Tbio AGXT2 Alanine--glyoxylate aminotransferase 2, mitochondrial

Protein Summary

Description

Can metabolize asymmetric dimethylarginine (ADMA) via transamination to alpha-keto-delta-(NN-dimethylguanidino) valeric acid (DMGV). ADMA is a potent inhibitor of nitric-oxide (NO) synthase, and this activity provides mechanism through which the kidney regulates blood pressure. The protein encoded by this gene is a class III pyridoxal-phosphate-dependent mitochondrial aminotransferase. It catalyzes the conversion of glyoxylate to glycine using L-alanine as the amino donor. It is an important regulator of methylarginines and is involved in the control of blood pressure in kidney. Polymorphisms in this gene affect methylarginine and beta-aminoisobutyrate metabolism, and are associated with carotid atherosclerosis. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Apr 2015]

Uniprot Accession IDs

• Q9BYV1
• B7ZM47
• E9PDL7
• Q53FB4
• Q53FY7
• Q53G03
• Q5W7Q1
• AGT 2

Gene Name

• AGXT2

Ensembl ID

• ENST00000231420
• ENSP00000231420
• ENSG00000113492
• ENST00000510428
• ENSP00000422799
• ENST00000618015
• ENSP00000479154

Symbol

• AGT2
• AGT2
• BAIBA
• DAIBAT

Knowledge Table

Most Knowledge About	Knowledge Value (0 to 1 scale)
biological process	0.72
gene perturbation	0.68
cell line	0.62
protein domain	0.58
phenotype	0.54

Protein Classes

No PANTHER Classes or DTO Classes found

IDG Development Level Summary

Tdark

These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 74.02   (req: < 5)

Gene RIFs: 21   (req: <= 3)

Antibodies: 130   (req: <= 50)

Tbio

These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 74.02   (req: >= 5)

Gene RIFs: 21   (req: > 3)

Antibodies: 130   (req: > 50)

- OR - satisfy the following criterion:

Gene Ontology Terms: 8

Tchem

Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions

Active Ligand: 0

Tclin

Target has at least one approved drug - AND - satisfies the preceding conditions

Active Drug: 0